Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28scores

Joint Bone Spine

Volumn 81, Issue 1, 2014, Pages 37-40

  Atzeni, Fabiola ^a   Bongiovanni, Sara ^a   Marchesoni, Antonio ^b   Filippini, Matteo ^c   Caporali, Roberto ^d   Gorla, Roberto ^c   Cavagna, Lorenzo ^d   Favalli, Ennio Giulio ^b   Saccardo, Francesco ^e   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UOC Day Hospital of Rheumatology   (Italy)

^c Rheumatology and Immunology Unit   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Ospedale di Saronno   (Italy)

Author keywords

Anti TNF; DAS28 scores; High and moderate disease activity; Predictive factors

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COMORBIDITY; DAS28; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; TREATMENT RESPONSE; AGE; CONTROLLED STUDY; DISEASE DURATION; EULAR IMPROVEMENT CRITERIA; EVALUATION STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; MIDDLE AGED; PROGNOSIS; REGISTER; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893808326     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.04.005     Document Type: Article

References (13)

1. Listing J., Strangfeld A., Rau R., et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006, 8:R66.
2. Hyrich K.L., Watson K.D., Silman A.J., et al. Predictors of response to anti-TNFalpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006, 45:1558-1565.
3. Burmester G.R., Ferraccioli G., Flipo R.M., et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2008, 59:32-34.
4. Kristensen L.E., Kapetanovic M.C., Gulfe A., et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology 2008, 47:495-499.
5. Felson D.T., Anderson J.J., Boers M., et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735.
6. Hyrich K.L., Deighton C., Watson K.D., et al. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) 2009, 48:1323-1327.
7. Katchamart W., Johnson S., Lin H.J., et al. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 2010, 62:1128-1143.
8. Sarzi-Puttini P., Antivalle M., Marchesoni A., et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo 2008, 60:290-295.
9. Valesini G., Montecucco C., Cutolo M. Anti-TNF treatment for rheumatoid arthritis. Clin Exp Rheum 2006, 4:414-423.
10. Makinen H., Kautiainen H., Hannonen P., et al. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Ann Rheum Dis 2005, 64:1410-1413.
11. Caporali R., Conti F., Alivernini S., et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol 2011, 29:S7-S14.
12. Atzeni F., Antivalle M., Pallavicini F.B., et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:431-437.
13. Straub R.H., Harle P., Sarzi-Puttini P., et al. Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinflammatory action. Arthritis Rheum 2006, 54:2039-2046.